Overview

A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma

Status:
Completed
Trial end date:
2004-04-27
Target enrollment:
Participant gender:
Summary
For patients with relapsed and refractory aggressive non-Hodgkin's lymphoma
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Treatments:
Albumin-Bound Paclitaxel
Lenograstim
Paclitaxel
Topotecan